4 results
The main objective of the present study is to investigate the association between in vivo regional synaptic loss ([11C]UCB-J PET), in vivo regional tau pathology ([18F]flortaucipir PET) and in vivo regional Aβ pathology ([18F]florbetapir PET).…
To compare overall survival (OS) of patients with metastatic (Stage IV) PDAC treated with BBI-608 plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine.
The SyncAV Post-Market Trial will evaluate changes in LV end-systolic volume (LVESV) between baseline (before CRT implant) and 12 months (post-randomization) in patients with CRT devices programmed with SyncAV compared to patients with CRT devices…
Primary objective of the study:* To compare overall survival (OS) in the General Population patients treated with BBI-608 plus biweekly FOLFIRI (Arm 1) versus biweekly FOLFIRI (Arm 2)* To compare OS in the pSTAT3-positive (pSTAT3(+)) Subpopulation…